In a partnering-crazy industry, when alliances are at record levels, it's easy to lose sight of the fact that alliances can often be acquisitions in disguise, once everything of value has been licensed off. With its latest deal with Procter & Gamble, which followed earlier deals with Amgen, Glaxo Wellcome, Medtronic, and Sumitomo, Regenergon Pharmaceuticals may be partnered out.
You may also be interested in...
In December, a California federal court ordered the US Environmental Protection Agency to amend its TSCA Chemical Data Reporting rule to address asbestos information-gathering “loopholes,” including a current exemption for asbestos that occurs as an impurity in raw materials such as cosmetic talc.
L'Aquila, Italy-based Dante Laboratories company announced a £30m investment in global surveillance of new variants of the SARS-CoV-2 virus. CEO Andrea Riposat discussed the purchase.
‘Everything is on the table,’ including invoking the Defense Production Act, White House COVID Coordinator Zients notes. Results of J&J’s Phase III vaccine trial expected ‘within next few days to a week.’